- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02149095
Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers
A Phase I, Open-label, Dose Escalation Study to Determine the Maximum Tolerated Dose and Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of TransCon PEG Treprostinil Administered as a Subcutaneous Injection in Healthy Adult Male Volunteers
TransCon PEG treprostinil is a novel prodrug form of treprostinil, in which treprostinil is reversibly conjugated via a four-arm branched polyethylene glycol (PEG) molecule. Reversible coupling of treprostinil to PEG should allow for a modified extended pharmacokinetic profile to achieve sustained plasma concentrations of treprostinil.
This will be the first investigation of TransCon PEG treprostinil in humans. This study aims to determine the maximum tolerated dose (MTD) and assess the safety, tolerability and pharmacokinetics of escalating single doses of a subcutaneous injection of TransCon PEG treprostinil.
Study Overview
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78744
- Ppd Development
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject gives voluntary written informed consent to participate in the study
- Subject is a healthy male between the ages of 18 and 50 years, inclusive, at Screening
- Subjects must weigh between 60 and 120 kg, inclusive, with a BMI between 19.0-32.0 kg/m2, inclusive at Screening
- Subject has a medical history, physical examination, vital signs, ECG and clinical laboratory results within normal limits or considered not clinically significant by the Investigator at Screening
- Subject agrees to abstain from taking any prescription medication for 14 days prior to check-in and to abstain from taking any non-prescription medications (except multivitamins) or herbal supplements for 7 days prior to check-in Baseline until discharge from the study (unless prescribed by the Investigator to treat an AE)
- Subject agrees to abstain from consuming alcohol from three days prior to check-in and until discharge from the study
- Subject agrees to refrain from strenuous exercise from check-in and until discharge from the study
- Subject is able to communicate effectively with study personnel and be considered reliable, willing and cooperative in terms of compliance with the protocol requirements
Exclusion Criteria:
- Subject has any clinically relevant abnormality identified during the screening physical examination, 12-lead ECG, or laboratory examinations
- Subject has a history of anaphylaxis, a previous documented hypersensitivity reaction, or a clinically significant idiosyncratic reaction to any drug
- Subject has a clinically significant history of neurological, cardiovascular, respiratory, endocrine, hematological, hepatic, renal, gastrointestinal, genitourinary, pulmonary, and/or musculoskeletal disease; glaucoma; a psychiatric disorder, or any other chronic disease, whether controlled by medication or not
- Subject has a history of postural hypotension, or unexplained syncope
- Subject has a blood pressure that is less than 85 mmHg systolic or 50 mmHg diastolic at Screening or Baseline
- Subject has a pulse rate that is greater than 90 bpm after sitting at rest for 5 minutes at Screening or Baseline
- Subject has a history of hypertension
- Subject has a blood pressure that is greater than 150 mmHg systolic or 90 mmHg diastolic at Screening or Baseline
- Subject has a predisposing condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs
- Subject has tested positive at the screening visit for HIV infection, HBsAg, or the HCV antibody
- Subject currently uses tobacco products or has a history of tobacco use within six months prior to Baseline
- Subject has a history of alcohol abuse or a history of or current impairment of organ function reasonably related to alcohol abuse
- Subject has a history of or current evidence of abuse of licit or illicit drugs or a positive urine screen for drugs of abuse
- Subject has a history of abnormal bleeding tendencies
- Subject has donated blood or plasma or has lost a significant volume of blood (greater than 450 mL) within four weeks prior to Baseline
- Subject has participated in any investigational drug study within 30 days prior to Screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TransCon PEG treprostinil
Dosing will begin at 0.116 mg/kg TransCon PEG treprostinil subcutaneous injection and the dose escalated in subsequent cohorts to MTD.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of treatment-emergent AEs
Time Frame: Day 43
|
Day 43
|
Maximum tolerated dose
Time Frame: 5 days
|
5 days
|
Treatment-emergent changes in clinical laboratory results
Time Frame: 43 days
|
43 days
|
Treatment-emergent changes in vital signs
Time Frame: 43 days
|
43 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the concentration versus time curve: (AUC)
Time Frame: 42 days
|
42 days
|
Maximum observed plasma concentration: Cmax
Time Frame: 42 days
|
42 days
|
Time to maximum observed plasma concentration: Tmax
Time Frame: 42 days
|
42 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TCP-PH-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PAH
-
The Cleveland ClinicWithdrawn
-
United TherapeuticsCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)Zymedi, Co., Ltd.Recruiting
-
Soroka University Medical CenterCompletedPOCUS Assessment During Ambulatory PAH ClinicIsrael
-
Complexa, Inc.Medpace, Inc.; Allegheny Singer Research Institute (also known as Allegheny... and other collaboratorsTerminated
-
Complexa, Inc.Philips Healthcare; Medpace, Inc.; Allegheny Singer Research Institute (also... and other collaboratorsTerminatedPAHUnited States, United Kingdom
-
University of Wisconsin, MadisonNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedPulmonary Arterial Hypertension (PAH)
-
University Medicine GreifswaldOMT GmbH & Co. KGUnknownPulmonary Arterial Hypertension | PAHGermany
-
University of GiessenPhilipps University Marburg Medical CenterRecruitingPulmonary Arterial Hypertension (PAH)Germany
Clinical Trials on TransCon PEG treprostinil
-
Ascendis Pharma A/STerminated
-
Ascendis Pharma A/SActive, not recruiting
-
Ascendis Pharma A/SActive, not recruitingAchondroplasiaUnited States, Australia, Austria, Denmark, Germany, Ireland, New Zealand, Portugal
-
Ascendis Pharma Growth Disorders A/SActive, not recruitingAchondroplasiaUnited States, Denmark, Ireland, New Zealand, Australia, Canada, Spain
-
Ascendis Pharma Growth Disorders A/SEnrolling by invitationAchondroplasiaUnited States, Australia, Denmark, Ireland, Austria
-
Ascendis Pharma A/SActive, not recruitingEndocrine System Diseases | Parathyroid Diseases | HypoparathyroidismUnited States, Canada, Denmark, Germany, Italy, Norway
-
United TherapeuticsTerminatedPulmonary Hypertension Associated With HFpEFUnited States
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States, Canada, India, United Kingdom, Spain, Israel, Australia, Belgium, France, Austria, China, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Sweden
-
Ascendis Pharma A/SCompleted
-
Ascendis Pharma A/SCompletedEndocrine System Diseases | Pituitary Diseases | Hormone Deficiency | Growth Hormone Deficiency, PediatricUnited States, Armenia, Belarus, Bulgaria, Georgia, Greece, Russian Federation, Ukraine, Australia, New Zealand, Poland